Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ESWT as a Treatment for Chronic NHO in TBI Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02331628
Recruitment Status : Active, not recruiting
First Posted : January 6, 2015
Last Update Posted : August 9, 2018
Sponsor:
Collaborators:
James Cook University, Queensland, Australia
University of Melbourne
Medispec
Information provided by (Responsible Party):
yaron sacher, Loewenstein Hospital

Brief Summary:

Effect of Extracorporeal Shock Wave Therapy on Chronic Neurogenic Heterotopic Ossification in Traumatic Brain Injured (TBI) patients

Chronic Neurogenic Heterotopic Ossification (NHO) - Heterotopic ossification is a well known late complication of traumatic brain injury. Extracorporeal Shock Wave Therapy - ESWT- is used in various medical situations and is being tested for feasibility of use in TBI patients.


Condition or disease Intervention/treatment Phase
TBI Traumatic Brain Injury Device: ESWT - Extracorporeal Shockwave Therapy Not Applicable

Detailed Description:

PROTOCOL SYNOPSIS Title Effect of Extracorporeal Shock Wave Therapy on Chronic Neurogenic Heterotopic Ossification in Traumatic Brain Injured (TBI) patients.

The investigators primary objective is to determine whether Extracorporeal Shock Wave Therapy (ESWT) is effective in reducing pain and improving function in people with traumatic brain injury who have heterotopic ossification around the hip or knee.

The investigators hypothesize that four applications of ESWT to the affected hip or knee joint in the patient group will demonstrate a positive physiological effect and this will lead to a reduction in pain and improved function.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Extracorporeal Shock Wave Therapy on Chronic Neurogenic Heterotopic Ossification in Traumatic Brain Injured Patients
Study Start Date : October 2014
Estimated Primary Completion Date : December 1, 2019
Estimated Study Completion Date : December 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Arm Intervention/treatment
No Intervention: Control
Usual care only will be provided during Baseline period and Follow-up period.
Experimental: ESWT - Extracorporeal Shockwave Therapy
Participants will receive 4 applications of extracorporeal shockwave therapy to the affected hip and/or knee over a period of 8 weeks (one dose every 2 weeks).
Device: ESWT - Extracorporeal Shockwave Therapy

Patients will receive:

  • Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\52 from baseline until and including week 14\52, one dose every two weeks ± 3 days), administered by the principal investigator.
  • Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.
  • The energy flux density (EFD) will be 'high level'
  • All participants will be supplied with headphones to reduce the noise level emitted by the machine.
Other Name: Minispec™ extracorporeal shockwave therapy




Primary Outcome Measures :
  1. Change in Visual Analogue Scale (VAS) from baseline to final assessment [ Time Frame: VAS will be assessed at two weekly intervals from week 0 (Baseline) until week 22, at week 26 and at week 38. ]
    The Visual Analogue Pain Scale (VAS) will be used in its format of the Faces Rating Scale (FRS). The FRS is in the format of six facial expressions suggesting various pain intensities. The patient will be asked to choose the face that best describes how they feel. The far left face indicates 'No hurt' and the far right face indicates 'Hurts worst'. The number below the face chosen will be documented.


Secondary Outcome Measures :
  1. Change from the 10 Metre Walk at baseline (if patient is ambulatory) [ Time Frame: At baseline; weeks 16, 26 and 38 ]
    Temporal and distance measures (velocity, stride length, cadence) will be measured using the 10 metre walk test.

  2. Change from the 6 Minute Walk at baseline (if patient is ambulatory) [ Time Frame: At baseline; weeks 16, 26 and 38 ]
    The patient is positioned at the start of the walking track and given the standardized instructions; "Walk as quickly as you can for six minutes to cover as much ground as possible. You may stop if you have to, but continue again as soon as you are able". On the instruction to start the therapist starts the stopwatch. At six minutes the patient is instructed to stop and the distance travelled is calculated. If the patient needs to stop, rest periods are included in the measurement time.

  3. Change from Functional Reach at baseline (if patient is able to stand) [ Time Frame: Every two weeks from date of baseline, week 0 up to week 22; then at week 26 and at week 38 ]

    The patient is instructed to stand next to, but not touching, a wall and position the arm that is closer to the wall at 90 degrees of shoulder flexion with a closed fist. The assessor records the starting position at the 3rd metacarpal head on the yardstick. The patient is instructed to "Reach as far as you can forward without taking a step." The location of the 3rd metacarpal is recorded. The difference between the start and end position is the reach distance, usually measured in centimeters.

    Three trials are done and the average of the last two is noted.


  4. Change from Modified Functional Reach at baseline (if FR not possible) [ Time Frame: Every two weeks from date of baseline, week 0 up to week 22; then at week 26 and at week 38 ]

    Modified Functional Reach (MFR) is a reliable measure of sitting balance for those patients unable to stand. This test is performed with a leveled yardstick mounted on the wall at the height of the patient's acromion level while sitting in a chair. Hips, knees and ankles are positioned at 90 degree of flexion, with feet flat on the floor. The initial reach is measured with the patient sitting against the back of the chair with the arm flexed to 90 degrees. The measurement is taken from the distal end of the third metacarpal along the yardstick. There are three conditions over three trials:

    • Sitting with the arm near the wall and leaning forward
    • Sitting with the back to the wall and leaning right
    • Sitting with the back to the wall leaning left. Instructions are leaning as far as possible in each direction without rotation and without touching the wall. The distance in centimetres covered in each direction will be recorded.


Other Outcome Measures:
  1. Change from Functional Independence Measure (FIM) at baseline [ Time Frame: At baseline; then at 8, 16, 26 and 38 weeks ]
    The Functional Independence Measure (FIM) assesses physical and cognitive disability. It consists of two subscales, motor and socio-cognitive with 18 assessable items in total. The tool is completed by observation of performance. The motor subscale, which is the portion to be assessed in this trial includes 13 items: eating, grooming bathing, dressing upper extremity, dressing lower extremity, bowel management, bladder management, transfers to bed, chair or wheelchair, transfer to tub, toilet and shower, walking or wheelchair propulsion and stair climbing. Each item is scored on a 7 point ordinal scale ranging from 1 (total dependence) to a score of 7 (total independence). Motor FIM scores range from 13 (total dependence) to 91 (total independence). Reliability and validity is well-established. The FIM has been translated into 10 languages, including English and Hebrew, the languages to be used in this study.

  2. Range of Motion [ Time Frame: Every two weeks from week 0 up to week 22; then at weeks 26 and 38 ]
    Range of Motion (ROM) of the affected hip and knee will be measured using a universal goniometer, using the protocol described by Clarkson (2005).

  3. Change from The European Quality Of Life -Dimensions questionnaire (EQ-5D) at baseline [ Time Frame: At baseline; 16,26 and 38 weeks ]
    The European Quality Of Life -Dimensions questionnaire (EQ-5D) is a standardised generic instrument designed for describing and valuing health by providing a single summary index value representing the overall health-related quality of life of an individual by quantifying a preference for his or her health state. The EQ-5D instrument consists of a self-classifier/ descriptive system to describe the respondent's own health in five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Respondents can value their health in each dimension at three ordinal levels: no problems, some or moderate problems, and severe or extreme problems. The second measurement component of the EQ-5D is a 20 cm vertical Visual Analogue Scale (EQ VAS) to rate the respondent's own health. The third component of the EQ-5D is a questionnaire on the respondent's background including medical history.

  4. Change from Plain X-ray at baseline [ Time Frame: At baseline and six months post first intervention ]
    Neurogenic Heterotopic Ossification (NHO) becomes evident on plain radiography approximately 2 to 6 weeks after clinical diagnosis (Freed, Hahn, Menter, & Dillon, 1982; Orzel & Rudd, 1985). An X-ray view will be set up for each patient and recorded so that it can be repeated. The view does not need to be a standard view; it is the patient's particular view that is important and reproducible. Measurements will be made along co-ordinates - set up for that patient - e.g. the largest and shortest diameters. Plain X-ray will be taken pre-intervention and six months post-intervention. Changes in the size of NHO will be calculated using UTHSCSA ImageTool (2002).plain radiography .

  5. Change from Serum Alkaline Phosphatase Levels (SAP) at baseline [ Time Frame: At base line, week 12, week 16, week 38 ]

    Overview Alkaline Phosphatase Uses Preparation Procedure Risks Results More on Healthline

    Part 1 of 7: Overview What Is an Alkaline Phosphatase Level Test?

    An alkaline phosphatase level test (ALP test) measures the amount of alkaline phosphatase enzyme in your bloodstream. The test requires a simple blood draw and is often a routine part of other blood tests.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age > 18 years
  • Brain injured patients with a diagnosis of NHO around the hip and/ or knee for a period of greater than one year.
  • Patients who are able, or legal guardians who are willing, to provide informed consent after both oral and written information.

Exclusion Criteria:

  • Pregnancy.
  • Rheumatoid arthritis, ankylosing spondylitis, or femoral neck fractures
  • Elevated serum alkaline phosphatase (SAP) levels and/or evidence of active bone remodelling in bone scan

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02331628


Locations
Layout table for location information
Israel
Loewenstein Rehabilitation Center
Ra'anana, Israel
Sponsors and Collaborators
Loewenstein Hospital
James Cook University, Queensland, Australia
University of Melbourne
Medispec
Investigators
Layout table for investigator information
Principal Investigator: Yaron Sacher, MD Loewenstein Hospital

Layout table for additonal information
Responsible Party: yaron sacher, Yaron Sacher M.D, Loewenstein Hospital
ClinicalTrials.gov Identifier: NCT02331628     History of Changes
Other Study ID Numbers: 20-13
First Posted: January 6, 2015    Key Record Dates
Last Update Posted: August 9, 2018
Last Verified: August 2018
Keywords provided by yaron sacher, Loewenstein Hospital:
TBI Traumatic Brain Injury
HO Heterotopic Ossification
NHO Neurogenic Heterotopic Ossification
ESWT Extracorporeal Shock Wave Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Brain Injuries, Traumatic
Ossification, Heterotopic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Pathologic Processes